Browse by People

Collapse authors list.
Berg, David D, Wiviott, Stephen D, Scirica, Benjamin M, Zelniker, Thomas A, Goodrich, Erica L, Jarolim, Petr, Mosenzon, Ofri, Cahn, Avivit, Bhatt, Deepak L, Leiter, Lawrence A et al (show 8 more authors) , McGuire, Darren K, Wilding, John PH ORCID: 0000-0003-2839-8404, Johanson, Per, Langkilde, Anna Maria, Raz, Itamar, Braunwald, Eugene, Sabatine, Marc S and Morrow, David A (2021) A Biomarker-Based Score for Risk of Hospitalization for Heart Failure in Patients With Diabetes. DIABETES CARE, 44 (11). pp. 2573-2581.

Collapse authors list.
Cahn, Avivit, Wiviott, Stephen D, Mosenzon, Ofri, Murphy, Sabina A, Goodrich, Erica L, Yanuv, Ilan, Rozenberg, Aliza, Wilding, John PH ORCID: 0000-0003-2839-8404, Leiter, Lawrence A, Bhatt, Deepak L et al (show 8 more authors) , McGuire, Darren K, Litwak, Leon, Kooy, Adriaan, Gause-Nilsson, Ingrid AM, Fredriksson, Martin, Langkilde, Anna Maria, Sabatine, Marc S and Raz, Itamar (2021) Cardiorenal outcomes with dapagliflozin by baseline glucose-lowering agents: Post hoc analyses fromDECLARE-TIMI58. DIABETES OBESITY & METABOLISM, 23 (1). pp. 29-38.

Collapse authors list.
Cahn, Avivit, Raz, Itamar, Leiter, Lawrence A, Mosenzon, Ofri, Murphy, Sabina A, Goodrich, Erica L, Yanuv, Ilan, Rozenberg, Aliza, Bhatt, Deepak L, McGuire, Darren K et al (show 5 more authors) , Wilding, John PH ORCID: 0000-0003-2839-8404, Gause-Nilsson, Ingrid AM, Langkilde, Anna Maria, Sabatine, Marc S and Wiviott, Stephen D (2021) Cardiovascular, Renal, and Metabolic Outcomes of Dapagliflozin Versus Placebo in a Primary Cardiovascular Prevention Cohort: Analyses From DECLARE-TIMI 58. DIABETES CARE, 44 (5). pp. 1159-1167.

Collapse authors list.
Zelniker, Thomas A, Wiviott, Stephen D, Raz, Itamar, Im, KyungAh, Goodrich, Erica L, Furtado, Remo HM, Bonaca, Marc P, Mosenzon, Ofri, Kato, Eri T, Cahn, Avivit et al (show 5 more authors) , Bhatt, Deepak L, Leiter, Lawrence A, McGuire, Darren K, Wilding, John PH ORCID: 0000-0003-2839-8404 and Sabatine, Marc S (2019) Comparison of the Effects of Glucagon-Like Peptide Receptor Agonists and Sodium-Glucose Co-Transporter 2 Inhibitors for Prevention of Major Adverse Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of Cardiovascular Outcomes Trials. Circulation, 139 (17). pp. 2022-2031.

Collapse authors list.
Raz, Itamar, Mosenzon, Ofri, Bonaca, Marc P, Cahn, Avivit, Kato, Eri T, Silverman, Michael G, Bhatt, Deepak L, Leiter, Lawrence A, McGuire, Darren K, Wilding, John PH ORCID: 0000-0003-2839-8404 et al (show 5 more authors) , Gause-Nilsson, Ingrid AM, Langkilde, Anna M, Johansson, Peter A, Sabatine, Marc S and Wiviott, Stephen D (2018) DECLARE-TIMI 58: Participants' baseline characteristics. DIABETES OBESITY & METABOLISM, 20 (5). pp. 1102-1110.

Collapse authors list.
Bonaca, Marc P, Wiviott, Stephen D, Zelniker, Thomas A, Mosenzon, Ofri, Bhatt, Deepak L, Leiter, Lawrence A, McGuire, Darren K, Goodrich, Erica L, De Mendonca Furtado, Remo Holanda, Wilding, John PH ORCID: 0000-0003-2839-8404 et al (show 8 more authors) , Cahn, Avivit, Gause-Nilsson, Ingrid AM, Johanson, Per, Fredriksson, Martin, Johansson, Peter A, Langkilde, Anna Maria, Raz, Itamar and Sabatine, Marc S (2020) Dapagliflozin and Cardiac, Kidney, and Limb Outcomes in Patients With and Without Peripheral Artery Disease in DECLARE-TIMI 58. Circulation, 142 (8). pp. 734-747.

Collapse authors list.
Mosenzon, Ofri, Raz, Itamar, Wiviott, Stephen D, Schechter, Meir, Goodrich, Erica L, Yanuv, Ilan, Rozenberg, Aliza, Murphy, Sabina A, Zelniker, Thomas A, Langkilde, Anna Maria et al (show 11 more authors) , Gause-Nilsson, Ingrid AM, Fredriksson, Martin, Johansson, Peter A, Wilding, John PH ORCID: 0000-0003-2839-8404, McGuire, Darren K, Bhatt, Deepak L, Leiter, Lawrence A, Cahn, Avivit, Dwyer, Jamie P, Heerspink, Hiddo JL and Sabatine, Marc S (2022) Dapagliflozin and Prevention of Kidney Disease Among Patients With Type 2 Diabetes: Post Hoc Analyses From the DECLARE-TIMI 58 Trial. DIABETES CARE, 45 (10). pp. 2350-2359.

Collapse authors list.
Zelniker, Thomas A, Raz, Itamar, Mosenzon, Ofri, Dwyer, Jamie P, Heerspink, Hiddo HJL, Cahn, Avivit, Goodrich, Erica L, Im, Kyungah, Bhatt, Deepak L, Leiter, Lawrence A et al (show 6 more authors) , McGuire, Darren K, Wilding, John PH ORCID: 0000-0003-2839-8404, Gause-Nilsson, Ingrid, Langkilde, Anna Maria, Sabatine, Marc S and Wiviott, Stephen D (2021) Effect of Dapagliflozin on Cardiovascular Outcomes According to Baseline Kidney Function and Albuminuria Status in Patients With Type 2 Diabetes: A Prespecified Secondary Analysis of a Randomized Clinical Trial. JAMA Cardiology, 6 (7). pp. 801-810.

Collapse authors list.
Kato, Eri T, Silverman, Michael G, Mosenzon, Ofri, Zelniker, Thomas A, Cahn, Avivit, Furtado, Remo HM, Kuder, Julia, Murphy, Sabina A, Bhatt, Deepak L, Leiter, Lawrence A et al (show 13 more authors) , McGuire, Darren K, Wilding, John PH ORCID: 0000-0003-2839-8404, Bonaca, Marc P, Ruff, Christian T, Desai, Akshay S, Goto, Shinya, Johansson, Peter A, Gause-Nilsson, Ingrid, Johanson, Per, Langkilde, Anna Maria, Raz, Itamar, Sabatine, Marc S and Wiviott, Stephen D (2019) Effect of Dapagliflozin on Heart Failure and Mortality in Type 2 Diabetes Mellitus. CIRCULATION, 139 (22). pp. 2528-2536.

Collapse authors list.
Mosenzon, Ofri, Wiviott, Stephen D, Cahn, Avivit, Rozenberg, Aliza, Yanuv, Ilan, Goodrich, Erica L, Murphy, Sabina A, Heerspink, Hiddo JL, Zelniker, Thomas A, Dwyer, Jamie P et al (show 11 more authors) , Bhatt, Deepak L, Leiter, Lawrence A, McGuire, Darren K, Wilding, John PH ORCID: 0000-0003-2839-8404, Kato, Eri T, Gause-Nilson, Ingrid AM, Fredriksson, Martin, Johansson, Peter A, Langkilde, Anna Maria, Sabatine, Marc S and Raz, Itamar (2019) Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE-TIMI 58 randomised trial. LANCET DIABETES & ENDOCRINOLOGY, 7 (8). pp. 606-617.

Collapse authors list.
Schechter, Meir, Wiviott, Stephen, Raz, Itamar, Goodrich, Erica L, Rozenberg, Aliza, Yanuv, Ilan, Murphy, Sabina A, Zelniker, Thomas A, Fredriksson, Martin, Johansson, Peter A et al (show 9 more authors) , Leiter, Lawrence A, Bhatt, Deepak L, McGuire, Darren K, Wilding, John PH ORCID: 0000-0003-2839-8404, Gause-Nilsson, Ingrid AM, Cahn, Avivit, Langkilde, Anna Maria, Sabatine, Marc S and Mosenzon, Ofri (2023) Effects of dapagliflozin on hospitalisations in people with type 2 diabetes: post-hoc analyses of the DECLARE-TIMI 58 trial. LANCET DIABETES & ENDOCRINOLOGY, 11 (4). pp. 233-241.

Collapse authors list.
Pollack, Rena, Raz, Itamar, Wiviott, Stephen D, Goodrich, Erica L, Murphy, Sabina A, Yanuv, Ilan, Rozenberg, Aliza, Mosenzon, Ofri, Langkilde, Anna Maria, Gause-Nilsson, Ingrid AM et al (show 6 more authors) , Bhatt, Deepak L, Leiter, Lawrence A, McGuire, Darren K, Wilding, John PH ORCID: 0000-0003-2839-8404, Sabatine, Marc S and Cahn, Avivit (2023) Efficacy and Safety of Dapagliflozin by Baseline Insulin Regimen and Dose: Post Hoc Analyses From DECLARE-TIMI 58. DIABETES CARE, 46 (1). pp. 156-164.

Collapse authors list.
Furtado, Remo HM, Raz, Itamar, Goodrich, Erica L, Murphy, Sabina A, Bhatt, Deepak L, Leiter, Lawrence A, McGuire, Darren K, Wilding, John PH ORCID: 0000-0003-2839-8404, Aylward, Philip, Dalby, Anthony J et al (show 10 more authors) , Dellborg, Mikael, Dimulescu, Doina, Nicolau, Jose C, Oude Ophuis, Anthonius JM, Cahn, Avivit, Mosenzon, Ofri, Gause-Nilsson, Ingrid, Langkilde, Anna Maria, Sabatine, Marc S and Wiviott, Stephen D (2022) Efficacy and Safety of Dapagliflozin in Type 2 Diabetes According to Baseline Blood Pressure: Observations From DECLARE-TIMI 58 Trial. CIRCULATION, 145 (21). pp. 1581-1591.

Collapse authors list.
Cahn, Avivit, Mosenzon, Ofri, Wiviott, Stephen D, Rozenberg, Aliza, Yanuv, Ilan, Goodrich, Erica L, Murphy, Sabina A, Bhatt, Deepak L, Leiter, Lawrence A, McGuire, Darren K et al (show 7 more authors) , Wilding, John PH ORCID: 0000-0003-2839-8404, Gause-Nilsson, Ingrid AM, Fredriksson, Martin, Johansson, Peter A, Langkilde, Anna Maria, Sabatine, Marc S and Raz, Itamar (2020) Efficacy and Safety of Dapagliflozin in the Elderly: Analysis From the DECLARE-TIMI 58 Study. DIABETES CARE, 43 (2). pp. 468-475.

O'Neil, Patrick M, Birkenfeld, Andreas L, McGowan, Barbara, Mosenzon, Ofri, Pedersen, Sue D, Wharton, Sean, Carson, Charlotte Giwercman, Jepsen, Cecilie Heerdegen, Kabisch, Maria and Wilding, John PH ORCID: 0000-0003-2839-8404 (2018) Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial. LANCET, 392 (10148). pp. 637-649.

Collapse authors list.
Zelniker, Thomas A, Wiviott, Stephen D, Raz, Itamar, Im, Kyungah, Goodrich, Erica L, Bonaca, Marc P, Mosenzon, Ofri, Kato, Eri T, Cahn, Avivit, Furtado, Remo HM et al (show 5 more authors) , Bhatt, Deepak L, Leiter, Lawrence A, McGuire, Darren K, Wilding, John PH ORCID: 0000-0003-2839-8404 and Sabatine, Marc S (2019) SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. LANCET, 393 (10166). pp. 31-39.

Collapse authors list.
Cahn, Avivit, Raz, Itamar, Bonaca, Marc, Mosenzon, Ofri, Murphy, Sabina A, Yanuv, Ilan, Rozenberg, Aliza, Wilding, John PH ORCID: 0000-0003-2839-8404, Bhatt, Deepak L, McGuire, Darren K et al (show 9 more authors) , Gause-Nilsson, Ingrid AM, Fredriksson, Martin, Johansson, Peter A, Jermendy, Gyorgy, Hadjadj, Samy, Langkilde, Anna Maria, Sabatine, Marc S, Wiviott, Stephen D and Leiter, Lawrence A (2020) Safety of dapagliflozin in a broad population of patients with type 2 diabetes: Analyses from the DECLARE-TIMI 58 study. DIABETES OBESITY & METABOLISM, 22 (8). pp. 1357-1368.

Collapse authors list.
McEwan, Phil, Morgan, Angharad R, Boyce, Rebecca, Bergenheim, Klas, Gause-Nilsson, Ingrid AM, Bhatt, Deepak L, Leiter, Lawrence A, Johansson, Peter A, Mosenzon, Ofri, Cahn, Avivit et al (show 1 more authors) and Wilding, John PH ORCID: 0000-0003-2839-8404 (2021) The cost-effectiveness of dapagliflozin in treating high-risk patients with type 2 diabetes mellitus: An economic evaluation using data from the DECLARE-TIMI 58 trial. DIABETES OBESITY & METABOLISM, 23 (4). pp. 1020-1029.

Collapse authors list.
Wiviott, Stephen D, Raz, Itamar, Bonaca, Marc P, Mosenzon, Ofri, Kato, Eri T, Cahn, Avivit, Silverman, Michael G, Bansilal, Sameer, Bhatt, Deepak L, Leiter, Lawrence A et al (show 6 more authors) , McGuire, Darren K, Wilding, John PH ORCID: 0000-0003-2839-8404, Gause-Nilsson, Ingrid AM, Langkilde, Anna Maria, Johansson, Peter A and Sabatine, Marc S (2018) The design and rationale for the Dapagliflozin Effect on Cardiovascular Events (DECLARE)-TIMI 58 Trial. AMERICAN HEART JOURNAL, 200. pp. 83-89.

Collapse authors list.
O'Donoghue, Michelle L, Kato, Eri T, Mosenzon, Ofri, Murphy, Sabina A, Cahn, Avivit, Herrera, Marisol, Tankova, Tsvetalina, Smahelova, Alena, Merlini, Piera, Gause-Nilsson, Ingrid et al (show 8 more authors) , Langkilde, Anna Maria, McGuire, Darren K, Wilding, John PH ORCID: 0000-0003-2839-8404, Leiter, Larry A, Bhatt, Deepak L, Raz, Itamar, Sabatine, Marc S and Wiviott, Stephen D (2021) The efficacy and safety of dapagliflozin in women and men with type 2 diabetes mellitus. DIABETOLOGIA, 64 (6). pp. 1226-1234.